[A18-88] Atezolizumab (urothelial carcinoma, first-line treatment) - Benefit assessment according to §35a Social Code Book V (new scientific findings)
Last updated 01.04.2019
Commission awarded on 19.12.2018 by the Federal Joint Committee (G-BA).
First-line treatment of adult patients with locally advanced or metastatic urothelial carcinoma who are inelegible for cisplatin-containing first-line treatment and whose tumours have a PD-L1 expression ≥ 5%
Added benefit not proven due to lack of suitable study data
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.